BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kambadakone AR, Fung A, Gupta RT, Hope TA, Fowler KJ, Lyshchik A, Ganesan K, Yaghmai V, Guimaraes AR, Sahani DV, Miller FH. LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. Abdom Radiol (NY) 2018;43:56-74. [PMID: 28940042 DOI: 10.1007/s00261-017-1325-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Vernuccio F, Cannella R, Cabibbo G, Greco S, Celsa C, Matteini F, Giuffrida P, Midiri M, Di Marco V, Cammà C, Brancatelli G. Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals. Diagnostics 2022;12:1187. [DOI: 10.3390/diagnostics12051187] [Reference Citation Analysis]
2 Ding J, Long L, Zhang X, Chen C, Zhou H, Zhou Y, Wang Y, Jing X, Ye Z, Wang F. Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS. Eur Radiol 2021;31:847-54. [PMID: 32803416 DOI: 10.1007/s00330-020-07159-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
3 Kamali M, Clarke SE, Costa AF. Evaluation of liver MRI examinations with two dosages of gadobenate dimeglumine: a blinded intra-individual study. Abdom Radiol (NY) 2020;45:36-44. [PMID: 31372778 DOI: 10.1007/s00261-019-02158-1] [Reference Citation Analysis]
4 Tom WJ, Xu X, Vahdat N, Cassidy F, Aganovic L. Follicular pancreatitis: A rare pancreatic inflammatory pseudotumor. Clin Imaging 2020;59:39-44. [PMID: 31756593 DOI: 10.1016/j.clinimag.2019.08.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
5 Cannella R, Cammà C, Matteini F, Celsa C, Giuffrida P, Enea M, Comelli A, Stefano A, Cammà C, Midiri M, Lagalla R, Brancatelli G, Vernuccio F. Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC. Diagnostics 2022;12:1308. [DOI: 10.3390/diagnostics12061308] [Reference Citation Analysis]
6 Costa AF, Peet K. Contrast media injection protocol for portovenous phase abdominal CT: does a fixed injection duration improve hepatic enhancement over a fixed injection rate? Abdom Radiol (NY) 2021;46:2968-75. [PMID: 33386915 DOI: 10.1007/s00261-020-02919-3] [Reference Citation Analysis]
7 Chernyak V, Fowler KJ, Heiken JP, Sirlin CB. Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS): Use of Gadoxetate Disodium and LI-RADS. J Magn Reson Imaging 2019;49:1236-52. [DOI: 10.1002/jmri.26540] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
8 Haj-mirzaian A, Kadivar A, Kamel IR, Zaheer A. Updates on Imaging of Liver Tumors. Curr Oncol Rep 2020;22. [DOI: 10.1007/s11912-020-00907-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
9 Vernuccio F, Cannella R, Bartolotta TV, Galia M, Tang A, Brancatelli G. Advances in liver US, CT, and MRI: moving toward the future. Eur Radiol Exp 2021;5:52. [PMID: 34873633 DOI: 10.1186/s41747-021-00250-0] [Reference Citation Analysis]
10 Shropshire EL, Chaudhry M, Miller CM, Allen BC, Bozdogan E, Cardona DM, King LY, Janas GL, Do RK, Kim CY, Ronald J, Bashir MR. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy. Radiology. 2019;292:226-234. [PMID: 31038409 DOI: 10.1148/radiol.2019182135] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 13.3] [Reference Citation Analysis]
11 Cannella R, Vernuccio F, Antonucci M, Gagliano DS, Matteini F, Midiri M, Brancatelli G. LI-RADS ancillary features favoring benignity: is there a role in LR-5 observations? Eur Radiol 2021. [PMID: 34545444 DOI: 10.1007/s00330-021-08267-0] [Reference Citation Analysis]
12 Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, Minter RM, Lairmore TC, Tseng JF, Zeh HJ, Libutti SK, Singh G, Lee JE, Hope TA, Kim MK, Menda Y, Halfdanarson TR, Chan JA, Pommier RF. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020;49:1-33. [PMID: 31856076 DOI: 10.1097/mpa.0000000000001454] [Cited by in Crossref: 56] [Cited by in F6Publishing: 23] [Article Influence: 28.0] [Reference Citation Analysis]
13 Li S, Zhou L, Chen R, Chen Y, Niu Z, Qian L, Fang Y, Xu L, Xu H, Zhang L. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma. Clin Radiol 2021;76:161.e1-161.e10. [PMID: 33198943 DOI: 10.1016/j.crad.2020.10.009] [Reference Citation Analysis]
14 Bartolotta TV, Terranova MC, Gagliardo C, Taibbi A. CEUS LI-RADS: a pictorial review. Insights Imaging. 2020;11:9. [PMID: 32020352 DOI: 10.1186/s13244-019-0819-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
15 Consul N, Sirlin CB, Chernyak V, Fetzer DT, Masch WR, Arora SS, Do RKG, Marks RM, Fowler KJ, Borhani AA, Elsayes KM. Imaging Features at the Periphery: Hemodynamics, Pathophysiology, and Effect on LI-RADS Categorization. Radiographics 2021;41:1657-75. [PMID: 34559586 DOI: 10.1148/rg.2021210019] [Reference Citation Analysis]
16 Cannella R, Vernuccio F, Celsa C, Cabibbo G, Calvaruso V, Greco S, Battaglia S, Choudhury KR, Tang A, Midiri M, Di Marco V, Cammà C, Brancatelli G. Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals. Liver Int 2021;41:2179-88. [PMID: 33908147 DOI: 10.1111/liv.14914] [Reference Citation Analysis]
17 Quaia E. State of the Art: LI-RADS for Contrast-enhanced US. Radiology 2019;293:4-14. [DOI: 10.1148/radiol.2019190005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
18 Kamath A, Roudenko A, Hecht E, Sirlin C, Chernyak V, Fowler K, Mitchell DG. CT/MR LI-RADS 2018: clinical implications and management recommendations. Abdom Radiol (NY) 2019;44:1306-22. [PMID: 30671612 DOI: 10.1007/s00261-018-1868-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
19 Chernyak V, Flusberg M, Berman J, Fruitman KC, Kobi M, Fowler KJ, Sirlin CB. Liver Imaging Reporting and Data System Version 2018: Impact on Categorization and Hepatocellular Carcinoma Staging. Liver Transpl 2019;25:1488-502. [DOI: 10.1002/lt.25614] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
20 Abdel Razek AAK, El-Serougy LG, Saleh GA, Shabana W, Abd El-Wahab R. Liver Imaging Reporting and Data System Version 2018: What Radiologists Need to Know. J Comput Assist Tomogr. 2020;44:168-177. [PMID: 32195795 DOI: 10.1097/rct.0000000000000995] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 11.5] [Reference Citation Analysis]
21 Vernuccio F, Cannella R, Choudhury KR, Meyer M, Furlan A, Marin D. Hepatobiliary phase hypointensity predicts progression to hepatocellular carcinoma for intermediate-high risk observations, but not time to progression. Eur J Radiol 2020;128:109018. [PMID: 32388318 DOI: 10.1016/j.ejrad.2020.109018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Vernuccio F, Cannella R, Meyer M, Choudhoury KR, Gonzáles F, Schwartz FR, Gupta RT, Bashir MR, Furlan A, Marin D. LI-RADS: Diagnostic Performance of Hepatobiliary Phase Hypointensity and Major Imaging Features of LR-3 and LR-4 Lesions Measuring 10-19 mm With Arterial Phase Hyperenhancement. AJR Am J Roentgenol 2019;213:W57-65. [PMID: 31039012 DOI: 10.2214/AJR.18.20979] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
23 M Cunha G, Fowler KJ, Roudenko A, Taouli B, Fung AW, Elsayes KM, Marks RM, Cruite I, Horvat N, Chernyak V, Sirlin CB, Tang A. How to Use LI-RADS to Report Liver CT and MRI Observations. Radiographics 2021;41:1352-67. [PMID: 34297631 DOI: 10.1148/rg.2021200205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Cunha GM, Tamayo-Murillo DE, Fowler KJ. LI-RADS and transplantation: challenges and controversies. Abdom Radiol (NY) 2021;46:29-42. [PMID: 31696268 DOI: 10.1007/s00261-019-02311-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
25 Ringe KI, Gut A, Grenacher L, Juchems M, Kukuk G, Wessling J, Schreyer AG. LI-RADS in the year 2020 - Are you already using it or still considering? Rofo 2021;193:186-93. [PMID: 32688423 DOI: 10.1055/a-1212-5915] [Reference Citation Analysis]
26 Ghadimi M, Birnbaum J, Kamel IR, Sirlin CB, Chernyak V. What proportion of LI-RADS 5 observations reported in clinical practice do not meet LI-RADS 5 criteria? Eur Radiol 2021. [PMID: 34807269 DOI: 10.1007/s00330-021-08389-5] [Reference Citation Analysis]
27 Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, Kono Y, Do RK, Mitchell DG, Singal AG, Tang A, Sirlin CB. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology 2018;289:816-30. [PMID: 30251931 DOI: 10.1148/radiol.2018181494] [Cited by in Crossref: 212] [Cited by in F6Publishing: 196] [Article Influence: 53.0] [Reference Citation Analysis]
28 Horvat N, Monti S, Oliveira BC, Rocha CCT, Giancipoli RG, Mannelli L. State of the art in magnetic resonance imaging of hepatocellular carcinoma. Radiol Oncol. 2018;52:353-364. [PMID: 30511939 DOI: 10.2478/raon-2018-0044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
29 . AIUM Practice Parameter for the Performance of Contrast‐Enhanced Ultrasound Examinations. J Ultrasound Med 2020;39:421-9. [DOI: 10.1002/jum.15204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
30 Cannella R, Dioguardi Burgio M, Beaufrère A, Trapani L, Paradis V, Hobeika C, Cauchy F, Bouattour M, Vilgrain V, Sartoris R, Ronot M. Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS. JHEP Rep 2021;3:100380. [PMID: 34825155 DOI: 10.1016/j.jhepr.2021.100380] [Reference Citation Analysis]
31 Elsayes KM, Kielar AZ, Elmohr MM, Chernyak V, Masch WR, Furlan A, Marks RM, Cruite I, Fowler KJ, Tang A, Bashir MR, Hecht EM, Kamaya A, Jambhekar K, Kamath A, Arora S, Bijan B, Ash R, Kassam Z, Chaudhry H, McGahan JP, Yacoub JH, McInnes M, Fung AW, Shanbhogue K, Lee J, Deshmukh S, Horvat N, Mitchell DG, Do RKG, Surabhi VR, Szklaruk J, Sirlin CB. White paper of the Society of Abdominal Radiology hepatocellular carcinoma diagnosis disease-focused panel on LI-RADS v2018 for CT and MRI. Abdom Radiol (NY) 2018;43:2625-42. [PMID: 30155697 DOI: 10.1007/s00261-018-1744-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 9.5] [Reference Citation Analysis]